{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:34:14Z","timestamp":1793068454367,"version":"4.5.0"},"reference-count":105,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T00:00:00Z","timestamp":1661904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Numerous studies show a modification of the gut microbiota in patients with obesity or diabetes. Animal studies have also shown a causal role of gut microbiota in liver metabolic disorders including steatosis whereas the human situation is less clear. Patients with metabolic dysfunction associated fatty liver disease (MAFLD) also have a modification in their gut microbiota composition but the changes are not fully characterized. The absence of consensus on a precise signature is probably due to disease heterogeneity, possible concomitant medications and different selection or evaluation criteria. The most consistent changes were increased relative abundance of Proteobacteria, Enterobacteriaceae and Escherichia species and decreased abundance of Coprococcus and Eubacterium. Possible mechanisms linking the microbiota and MAFLD are increased intestinal permeability with translocation of microbial products into the portal circulation, but also changes in the bile acids and production of microbial metabolites such as ethanol, short chain fatty acids and amino acid derivatives able to modulate liver metabolism and inflammation. Several interventional studies exist that attempt to modulate liver disease by administering antibiotics, probiotics, prebiotics, synbiotics, postbiotics or fecal transplantation. In conclusion, there are both gaps and hopes concerning the interest of gut microbiome evaluation for diagnosis purposes of MAFLD and for new therapeutic developments that are often tested on small size cohorts.<\/jats:p>","DOI":"10.3390\/cells11172718","type":"journal-article","created":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T23:53:21Z","timestamp":1661990001000},"page":"2718","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Targeting the Gut Microbiome to Treat Metabolic Dysfunction-Associated Fatty Liver Disease: Ready for Prime Time?"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7651-9314","authenticated-orcid":false,"given":"Nicolas","family":"Lanthier","sequence":"first","affiliation":[{"name":"Service d\u2019H\u00e9pato-Gastroent\u00e9rologie, Cliniques Universitaires Saint-Luc, UCLouvain, 1200 Brussels, Belgium"},{"name":"Laboratory of Gastroenterology and Hepatology, Institut de Recherche Exp\u00e9rimentale et Clinique, UCLouvain, 1200 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2115-6082","authenticated-orcid":false,"given":"Nathalie","family":"Delzenne","sequence":"additional","affiliation":[{"name":"Metabolism and Nutrition Research Group, Louvain Drug Research Institute, UCLouvain, 1200 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s11154-020-09572-7","article-title":"Microbiome response to diet: Focus on obesity and related diseases","volume":"21","author":"Delzenne","year":"2020","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.2337\/db06-1491","article-title":"Metabolic endotoxemia initiates obesity and insulin resistance","volume":"56","author":"Cani","year":"2007","journal-title":"Diabetes"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.2337\/dc10-2197","article-title":"Bacterial Endotoxin Activity in Human Serum Is Associated With Dyslipidemia, Insulin Resistance, Obesity, and Chronic Inflammation","volume":"34","author":"Lassenius","year":"2011","journal-title":"Diabetes Care"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/nature05414","article-title":"An Obesity-Associated Gut Microbiome with Increased Capacity for Energy Harvest","volume":"444","author":"Turnbaugh","year":"2006","journal-title":"Nature"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Vrieze, A., Van Nood, E., Holleman, F., Saloj\u00e4rvi, J., Kootte, R.S., Bartelsman, J.F., Dallinga-Thie, G.M., Ackermans, M.T., Serlie, M.J., and Oozeer, R. (2012). Transfer of Intestinal Microbiota from Lean Donors Increases Insulin Sensitivity in Individuals with Metabolic Syndrome. Gastroenterology, 143.","DOI":"10.1053\/j.gastro.2012.06.031"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s40168-020-00875-0","article-title":"Microbiome definition re-visited: Old concepts and new challenges","volume":"8","author":"Berg","year":"2020","journal-title":"Microbiome"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMc1710026","article-title":"Health Effects of Overweight and Obesity in 195 Countries","volume":"377","author":"Reilly","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_8","first-page":"55","article-title":"The Belgian Association for Study of the Liver Guidance Document on the Management of Adult and Paediatric Non-Alcoholic Fatty Liver Disease","volume":"81","author":"Francque","year":"2018","journal-title":"Acta Gastro-Enterol. Belg."},{"key":"ref_9","first-page":"513","article-title":"Metabolic dysfunction-associated fatty liver disease: A new clearer nomenclature with positive diagnostic criteria","volume":"83","author":"Lanthier","year":"2020","journal-title":"Acta Gastro-Enterol. Belg."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S2468-1253(22)00062-0","article-title":"Global multi-stakeholder endorsement of the MAFLD definition","volume":"7","author":"Bugianesi","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/MCO.0b013e32832c7819","article-title":"The metabolic syndrome: How it may influence hepatic stellate cell activation and hepatic fibrosis","volume":"12","author":"Lanthier","year":"2009","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"346","DOI":"10.51821\/85.2.9775","article-title":"Non-Invasive Screening, Staging and Man-agement of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) in Type 2 Diabetes Mellitus Patients: What Do We Know so Far?","volume":"85","author":"Binet","year":"2022","journal-title":"Acta Gastroenterol. Belg."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Etienne, Q., Lebrun, V., Komuta, M., Navez, B., Thissen, J.-P., Leclercq, I.A., and Lanthier, N. (2022). Fetuin-A in Activated Liver Macrophages Is a Key Feature of Non-Alcoholic Steatohepatitis. Metabolites, 12.","DOI":"10.3390\/metabo12070625"},{"key":"ref_14","first-page":"405","article-title":"Physiopathologie de La NASH: De Nouveaux Facteurs de Risque Identifi\u00e9s?","volume":"139","author":"Lanthier","year":"2020","journal-title":"Louv. Med."},{"key":"ref_15","first-page":"339","article-title":"NASH: A welfare disease with emerging questions and adequate answer attempts","volume":"83","author":"Lanthier","year":"2020","journal-title":"Acta Gastroenterol. Belg."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Salavrakos, M., de Timary, P., Moreno, A.R., Thissen, J.-P., and Lanthier, N. (2021). Fructoholism in adults: The importance of personalised care in metabolic dysfunction-associated fatty liver disease. JHEP Rep., 4.","DOI":"10.1016\/j.jhepr.2021.100396"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.4254\/wjh.v7.i19.2184","article-title":"Targeting Kupffer cells in non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis: Why and how?","volume":"7","author":"Lanthier","year":"2015","journal-title":"World J. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"660179","DOI":"10.3389\/fimmu.2021.660179","article-title":"The Role of the Gut-Liver Axis in Metabolic Dysfunction-Associated Fatty Liver Disease","volume":"12","author":"Albillos","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"12324","DOI":"10.1038\/s41598-019-48784-z","article-title":"Cholestasis induced by bile duct ligation promotes changes in the intestinal microbiome in mice","volume":"9","author":"Patterson","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1042\/CS20200022","article-title":"Cirrhosis and insulin resistance: Current knowledge, pathophysiological mechanisms, complications and potential treatments","volume":"134","author":"Clarembeau","year":"2020","journal-title":"Clin. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/hep.24423","article-title":"Characterization of fecal microbial communities in patients with liver cirrhosis","volume":"54","author":"Chen","year":"2011","journal-title":"Hepatology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1073\/pnas.0605374104","article-title":"Mechanisms underlying the resistance to diet-induced obesity in germ-free mice","volume":"104","author":"Manchester","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"15718","DOI":"10.1073\/pnas.0407076101","article-title":"The Gut Microbiota as an Environmental Factor That Regulates Fat Storage","volume":"101","author":"Ding","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","first-page":"1787","article-title":"Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice","volume":"62","author":"Llopis","year":"2012","journal-title":"Gut"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41598-017-01751-y","article-title":"Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/MCO.0000000000000584","article-title":"Microbiota and nonalcoholic fatty liver disease","volume":"22","author":"Knudsen","year":"2019","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1080\/19490976.2019.1681861","article-title":"Lower gut microbiome diversity and higher abundance of proinflammatory genus Collinsella are associated with biopsy-proven nonalcoholic steatohepatitis","volume":"11","author":"Astbury","year":"2019","journal-title":"Gut Microbes"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"146587","DOI":"10.1016\/j.gene.2022.146587","article-title":"Metagenomic identification of gut microbiota distribution on the colonic mucosal biopsy samples in patients with non-alcoholic fatty liver disease","volume":"833","author":"Delik","year":"2022","journal-title":"Gene"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"32002","DOI":"10.1038\/srep32002","article-title":"Altered Fecal Microbiota Correlates with Liver Biochemistry in Nonobese Patients with Non-alcoholic Fatty Liver Disease","volume":"6","author":"Wang","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1499-3872(17)60019-5","article-title":"Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease","volume":"16","author":"Shen","year":"2017","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41598-020-79718-9","article-title":"Microbiota analysis and transient elastography reveal new extra-hepatic components of liver steatosis and fibrosis in obese patients","volume":"11","author":"Lanthier","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4982","DOI":"10.1038\/s41467-020-18754-5","article-title":"Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD","volume":"11","author":"Lee","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/hep.28356","article-title":"The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota","volume":"63","author":"Boursier","year":"2016","journal-title":"Hepatology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41575-020-0269-9","article-title":"Gut microbiota and human NAFLD: Disentangling microbial signatures from metabolic disorders","volume":"17","author":"Vigliotti","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Sharpton, S.R., Podlaha, O., Chuang, J.-C., Gindin, Y., Myers, R.P., and Loomba, R. (2022). Changes in the gut microbiome associated with liver stiffness improvement in nonalcoholic steatohepatitis. Ther. Adv. Gastroenterol., 15.","DOI":"10.1177\/17562848221098243"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.jhep.2021.12.003","article-title":"Promises of microbiome-based therapies","volume":"76","author":"Bajaj","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jhep.2021.11.029","article-title":"The fecal mycobiome in non-alcoholic fatty liver disease","volume":"76","author":"Demir","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1053\/j.gastro.2020.07.005","article-title":"Intestinal Virome Signature Associated With Severity of Nonalcoholic Fatty Liver Disease","volume":"159","author":"Lang","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41591-018-0061-3","article-title":"Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women","volume":"24","author":"Hoyles","year":"2018","journal-title":"Nat. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/hep.26093","article-title":"Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH","volume":"57","author":"Zhu","year":"2013","journal-title":"Hepatology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/hep.28572","article-title":"Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach","volume":"65","author":"Nobili","year":"2017","journal-title":"Hepatology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.cmet.2017.04.001","article-title":"Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease","volume":"25","author":"Loomba","year":"2017","journal-title":"Cell Metab."},{"key":"ref_43","first-page":"G84","article-title":"Role of gut microbiota in liver disease","volume":"318","author":"Albhaisi","year":"2020","journal-title":"Am. J. Physiol. Liver Physiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1002\/hep.22848","article-title":"Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease","volume":"49","author":"Miele","year":"2009","journal-title":"Hepatology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/hep.26937","article-title":"The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease","volume":"59","author":"Gadd","year":"2014","journal-title":"Hepatology"},{"key":"ref_46","first-page":"G107","article-title":"Kupffer cell activation is a causal factor for hepatic insulin resistance","volume":"298","author":"Lanthier","year":"2010","journal-title":"Am. J. Physiol. Liver Physiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1096\/fj.11-189472","article-title":"Kupffer cell depletion prevents but has no therapeutic effect on metabolic and inflammatory changes induced by a high-fat diet","volume":"25","author":"Lanthier","year":"2011","journal-title":"FASEB J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"595371","DOI":"10.3389\/fmed.2021.595371","article-title":"Oxidative Stress in Non-alcoholic Fatty Liver Disease. An Updated Mini Review","volume":"8","author":"Bovi","year":"2021","journal-title":"Front. Med."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Del Ben, M., Polimeni, L., Carnevale, R., Bartimoccia, S., Nocella, C., Baratta, F., Loffredo, L., Pignatelli, P., Violi, F., and Angelico, F. (2014). NOX2-generated oxidative stress is associated with severity of ultrasound liver steatosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol., 14.","DOI":"10.1186\/1471-230X-14-81"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/gutjnl-2018-316307","article-title":"Small metabolites, possible big changes: A microbiota-centered view of non-alcoholic fatty liver disease","volume":"68","author":"Chu","year":"2018","journal-title":"Gut"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1782157","DOI":"10.1080\/19490976.2020.1782157","article-title":"Intestinal permeability, microbial translocation, changes in duodenal and fecal microbiota, and their associations with alcoholic liver disease progression in humans","volume":"12","author":"Maccioni","year":"2020","journal-title":"Gut Microbes"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Maccioni, L., Leclercq, I.A., Schnabl, B., and St\u00e4rkel, P. (2021). Host Factors in Dysregulation of the Gut Barrier Function during Alcohol-Associated Liver Disease. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222312687"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Maccioni, L., Loriot, A., Dewulf, J., Bommer, G., Horsmans, Y., Lanthier, N., Leclercq, I., Schnabl, B., and St\u00e4rkel, P. (2022). Duodenal CD8 + T resident memory cell apoptosis contributes to gut barrier dysfunction and microbial translocation in early alcohol-associated liver disease in humans. Aliment. Pharmacol. Ther.","DOI":"10.1111\/apt.17177"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/apt.15035","article-title":"Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD","volume":"49","author":"Caussy","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.nupar.2020.04.003","article-title":"Les nouveaux traitements de la st\u00e9atoh\u00e9patite non-alcoolique","volume":"34","author":"Lanthier","year":"2020","journal-title":"Nutrition Clinique et Me\u00b4tabolisme"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3389\/fmed.2020.00544","article-title":"Bile Acids and FXR: Novel Targets for Liver Diseases","volume":"7","author":"Stofan","year":"2020","journal-title":"Front. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/imr.12579","article-title":"Interactions between bile salts, gut microbiota, and hepatic innate immunity","volume":"279","author":"Schubert","year":"2017","journal-title":"Immunol. Rev."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1093\/jn\/nxab032","article-title":"Hepatoprotective Effects of Indole, a Gut Microbial Metabolite, in Leptin-Deficient Obese Mice","volume":"151","author":"Knudsen","year":"2021","journal-title":"J. Nutr."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/hep.31115","article-title":"Indole Alleviates Diet-Induced Hepatic Steatosis and Inflammation in a Manner Involving Myeloid Cell 6-Phosphofructo-2-Kinase\/Fructose-2,6-Biphosphatase 3","volume":"72","author":"Ma","year":"2020","journal-title":"Hepatology"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Shimada, Y., Kinoshita, M., Harada, K., Mizutani, M., Masahata, K., Kayama, H., and Takeda, K. (2013). Commensal Bacteria-Dependent Indole Production Enhances Epithelial Barrier Function in the Colon. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0080604"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Yuan, J., Chen, C., Cui, J., Lu, J., Yan, C., Wei, X., Zhao, X., Li, N., Li, S., and Xue, G. (2019). Fatty Liver Disease Caused by High-Alcohol-Producing Klebsiella pneumoniae. Cell Metab., 30.","DOI":"10.1016\/j.cmet.2019.11.006"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Zhao, M., Zhao, L., Xiong, X., He, Y., Huang, W., Liu, Z., Ji, L., Pan, B., Guo, X., and Wang, L. (2020). TMAVA, a Metabolite of Intestinal Microbes, Is Increased in Plasma From Patients With Liver Steatosis, Inhibits \u03b3-Butyrobetaine Hydroxylase, and Exacerbates Fatty Liver in Mice. Gastroenterology, 158.","DOI":"10.1053\/j.gastro.2020.02.033"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"567654","DOI":"10.3389\/fmicb.2020.567654","article-title":"Microbial Metabolites: Critical Regulators in NAFLD","volume":"11","author":"Dai","year":"2020","journal-title":"Front. Microbiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.2337\/db08-1637","article-title":"Butyrate Improves Insulin Sensitivity and Increases Energy Expenditure in Mice","volume":"58","author":"Gao","year":"2009","journal-title":"Diabetes"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41586-021-03233-8","article-title":"Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH","volume":"592","author":"Dudek","year":"2021","journal-title":"Nature"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"104051","DOI":"10.1016\/j.ebiom.2022.104051","article-title":"Breath volatile metabolome reveals the impact of dietary fibres on the gut microbiota: Proof of concept in healthy volunteers","volume":"80","author":"Neyrinck","year":"2022","journal-title":"eBioMedicine"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1862028","DOI":"10.1080\/19490976.2020.1862028","article-title":"Noninvasive monitoring of fibre fermentation in healthy volunteers by analyzing breath volatile metabolites: Lessons from the FiberTAG intervention study","volume":"13","author":"Neyrinck","year":"2021","journal-title":"Gut Microbes"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jnutbio.2010.10.008","article-title":"Dietary modulation of clostridial cluster XIVa gut bacteria (Roseburia spp.) by chitin-glucan fiber improves host metabolic alterations induced by high-fat diet in mice","volume":"23","author":"Neyrinck","year":"2012","journal-title":"J. Nutr. Biochem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s41591-018-0060-4","article-title":"Genetic deficiency of indoleamine 2,3-dioxygenase promotes gut microbiota-mediated metabolic health","volume":"24","author":"Laurans","year":"2018","journal-title":"Nat. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1097\/MEG.0000000000000348","article-title":"Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease","volume":"27","author":"Gangarapu","year":"2015","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/hepr.12904","article-title":"Rifaximin in non-alcoholic steatohepatitis: An open-label pilot study","volume":"48","author":"Cobbold","year":"2017","journal-title":"Hepatol. Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1097\/MEG.0000000000001232","article-title":"Rifaximin in nonalcoholic fatty liver disease: Hit multiple targets with a single shot","volume":"30","author":"Mousa","year":"2018","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"41","DOI":"10.15403\/jgld.2014.1121.271.kby","article-title":"A Multi-strain Probiotic Reduces the Fatty Liver Index, Cytokines and Aminotransferase levels in NAFLD Patients: Evidence from a Randomized Clinical Trial","volume":"27","author":"Kobyliak","year":"2018","journal-title":"J. Gastrointest. Liver Dis."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-019-0495-2","article-title":"Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: A proof-of-concept exploratory study","volume":"25","author":"Depommier","year":"2019","journal-title":"Nat. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/sj.ejcn.1602127","article-title":"Effects of oligofructose on glucose and lipid metabolism in patients with nonalcoholic steatohepatitis: Results of a pilot study","volume":"59","author":"Daubioul","year":"2005","journal-title":"Eur. J. Clin. Nutr."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00394-018-1721-2","article-title":"Histological improvement of non-alcoholic steatohepatitis with a prebiotic: A pilot clinical trial","volume":"58","author":"Bomhof","year":"2019","journal-title":"Eur. J. Nutr."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/dom.13500","article-title":"The effects of dietary supplementation with inulin and inulin-propionate ester on hepatic steatosis in adults with non-alcoholic fatty liver disease","volume":"21","author":"Chambers","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1016\/j.clnu.2020.04.005","article-title":"Link between gut microbiota and health outcomes in inulin -treated obese patients: Lessons from the Food4Gut multicenter randomized placebo-controlled trial","volume":"39","author":"Hiel","year":"2020","journal-title":"Clin. Nutr."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1136\/gutjnl-2019-319726","article-title":"Discovery of the gut microbial signature driving the efficacy of prebiotic intervention in obese patients","volume":"69","author":"Rodriguez","year":"2020","journal-title":"Gut"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/1751-2980.12561","article-title":"Treatment efficacy of a probiotic preparation for non-alcoholic steatohepatitis: A pilot trial","volume":"18","author":"Manzhalii","year":"2017","journal-title":"J. Dig. Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1093\/jn\/nxy088","article-title":"Daily Consumption of Synbiotic Yogurt Decreases Liver Steatosis in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial","volume":"148","author":"Bakhshimoghaddam","year":"2018","journal-title":"J. Nutr."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Scorletti, E., Afolabi, P.R., Miles, E.A., Smith, D.E., Almehmadi, A., AlShathry, A., Childs, C.E., Del Fabbro, S., Bilson, J., and Moyses, H.E. (2020). Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology, 158.","DOI":"10.1053\/j.gastro.2020.01.031"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.14309\/ajg.0000000000000661","article-title":"Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control Trial","volume":"115","author":"Craven","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"12","DOI":"10.14218\/ERHM.2018.00025","article-title":"Fecal Microbiota Transplantation for the Treatment of Nonalcoholic Fatty Liver Disease","volume":"4","author":"Xue","year":"2019","journal-title":"Explor. Res. Hypothesis Med."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"\u017b\u00f3\u0142kiewicz, J., Marzec, A., Ruszczy\u0144ski, M., and Feleszko, W. (2020). Postbiotics\u2014A Step Beyond Pre- and Probiotics. Nutrients, 12.","DOI":"10.3390\/nu12082189"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.3389\/fmicb.2016.01983","article-title":"Addressing the Antibiotic Resistance Problem with Probiotics: Reducing the Risk of Its Double-Edged Sword Effect","volume":"7","author":"Imperial","year":"2016","journal-title":"Front. Microbiol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jhep.2010.08.030","article-title":"A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis","volume":"54","author":"Ratziu","year":"2011","journal-title":"J. Hepatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/hep.510230624","article-title":"Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: A pilot study","volume":"23","author":"Laurin","year":"1996","journal-title":"Hepatology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/hep.20092","article-title":"Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial","volume":"39","author":"Lindor","year":"2004","journal-title":"Hepatology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1038\/s41424-018-0025-4","article-title":"Differential metabolic effects of oral butyrate treatment in lean versus metabolic syndrome subjects","volume":"9","author":"Bouter","year":"2018","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41575-021-00440-6","article-title":"The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics","volume":"18","author":"Salminen","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/s41575-021-00521-6","article-title":"Postbiotics\u2014When simplification fails to clarify","volume":"18","author":"Arioli","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jhep.2022.04.002","article-title":"Breakthroughs in therapies for NASH and remaining challenges","volume":"76","author":"Ratziu","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/hep.31624","article-title":"MRI-Proton Density Fat Fraction Treatment Response Criteria in Nonalcoholic Steatohepatitis","volume":"73","author":"Loomba","year":"2020","journal-title":"Hepatology"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Stine, J.G., Munaganuru, N., Barnard, A., Wang, J.L., Kaulback, K., Argo, C.K., Singh, S., Fowler, K.J., Sirlin, C.B., and Loomba, R. (2020). Change in MRI-PDFF and Histologic Response in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis. Clin. Gastroenterol. Hepatol., 19.","DOI":"10.1016\/j.cgh.2020.08.061"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.mib.2017.11.001","article-title":"Systematically investigating the impact of medication on the gut microbiome","volume":"39","author":"Maier","year":"2017","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1517\/17425255.2016.1121234","article-title":"The influence of gut microbiota on drug metabolism and toxicity","volume":"12","author":"Li","year":"2015","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_98","first-page":"616","article-title":"Targeting the gut microbiota to treat alcoholic liver diseases: Evidence and promises","volume":"83","author":"Leclercq","year":"2020","journal-title":"Acta Gastroenterol. Belg."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.alcohol.2008.08.006","article-title":"Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: A pilot study","volume":"42","author":"Kirpich","year":"2008","journal-title":"Alcohol"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/eci.12767","article-title":"Treatment of severe alcoholic hepatitis: Past, present and future","volume":"47","author":"Lanthier","year":"2017","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.bpg.2014.07.002","article-title":"Adipose tissues as endocrine target organs","volume":"28","author":"Lanthier","year":"2014","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11901-020-00505-1","article-title":"Accounting for the Placebo Effect and Optimizing Outcomes in Clinical Trials of Nonalcoholic Steatohepatitis (NASH)","volume":"19","author":"Noureddin","year":"2020","journal-title":"Curr. Hepatol. Rep."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1136\/gutjnl-2014-308778","article-title":"Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: Relationship with gut microbiome richness and ecology","volume":"65","author":"Dao","year":"2016","journal-title":"Gut"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Rodriguez, J., Neyrinck, A.M., Van Kerckhoven, M., Gianfrancesco, M.A., Renguet, E., Bertrand, L., Cani, P.D., Lanthier, N., Cnop, M., and Paquot, N. (2022). Physical activity enhances the improvement of body mass index and metabolism by inulin: A multicenter randomized placebo-controlled trial performed in obese individuals. BMC Med., 20.","DOI":"10.1186\/s12916-022-02299-z"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/17\/2718\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:21:06Z","timestamp":1760142066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/17\/2718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,31]]},"references-count":105,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["cells11172718"],"URL":"https:\/\/doi.org\/10.3390\/cells11172718","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,31]]}}}